Kura Oncology Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
Good afternoon, and welcome once again to Cowen and Company's Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen. It's my pleasure to moderate the discussion with Troy Wilson, the President and CEO of Kura.
Questions & Answers
Troy, some news this morning. Kura's got the abstract accepted at EHA. So maybe we'd start by laying the background and discussing what was presented at ASH. Could you provide some highlights from ziftomenib's ASH presentation as a way of setting the table for the EHA?
Sure. Yes, Phil, happy to do that. And thanks again for the invitation to attend the session. So at ASH 2022, back in December, we presented data from the Phase 1b study for ziftomenib for both NPM1-mutant and KMT2A-rearranged AML patients. Actually, we presented the entirety of the Phase 1 experience, the Phase 1a escalation, and in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |